These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30008379)

  • 21. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
    Liu L; Chen B; Qin S; Li S; He X; Qiu S; Zhao W; Zhao H
    Biochem Biophys Res Commun; 2010 Feb; 392(2):190-5. PubMed ID: 20060381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
    Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
    Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
    Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
    Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of CD22 by Chidamide promotes CAR T cells functionality.
    Yang X; Yu Q; Xu H; Zhou J
    Sci Rep; 2021 Oct; 11(1):20637. PubMed ID: 34667217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
    Lu X; Ning Z; Li Z; Cao H; Wang X
    Intractable Rare Dis Res; 2016 Aug; 5(3):185-91. PubMed ID: 27672541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response].
    Xu L; Tang HL; Gong X; Xin XL; Dong Y; Gao GX; Shu MM; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):450-4. PubMed ID: 25948203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
    Lun Y; Yang JJ; Wu Y
    J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HPLC-APCI-MS/MS method for the determination of catalpol in rat plasma and cerebrospinal fluid: application to an in vivo pharmacokinetic study.
    Wang Q; Xing M; Chen W; Zhang J; Qi H; Xu X
    J Pharm Biomed Anal; 2012 Nov; 70():337-43. PubMed ID: 22677654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study.
    Thappali SR; Varanasi KV; Veeraraghavan S; Vakkalanka SK; Mukkanti K
    J Mass Spectrom; 2012 Dec; 47(12):1612-9. PubMed ID: 23280750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
    Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
    Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
    Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of HS270, a new histone deacetylase inhibitor, in rat plasma by LC-MS/MS--application to a preclinical pharmacokinetic study.
    Zhong GP; Chen JY; Bi HC; Qin XL; Dai CL; Liu J; Chen X; Zeng GX; Huang ZY; Huang M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3452-8. PubMed ID: 21983196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
    Liu W; Zhao D; Liu T; Niu T; Song Y; Xu W; Jin J; Cai Q; Huang H; Li Z; Hou M; Zhang H; Zhou J; Hu J; Shen J; Shi Y; Yang Y; Zhang L; Zhao W; Ding K; Qiu L; Tan H; Zhang Z; Liu L; Wang J; Xu B; Zhou H; Gao G; Xue H; Bai O; Feng R; Huang X; Yang H; Yan X; Zeng Q; Liu P; Li W; Mao M; Su H; Wang X; Xu J; Zhou D; Zhang H; Ma J; Shen Z; Zhu J
    Front Oncol; 2021; 11():750323. PubMed ID: 34804937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chidamide in the treatment of peripheral T-cell lymphoma.
    Chan TS; Tse E; Kwong YL
    Onco Targets Ther; 2017; 10():347-352. PubMed ID: 28138258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid.
    Gu L; Ma M; Zhang Y; Zhang L; Zhang S; Huang M; Zhang M; Xin Y; Zheng G; Chen S
    Regul Toxicol Pharmacol; 2019 Oct; 107():104420. PubMed ID: 31295511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
    Gong K; Xie J; Yi H; Li W
    Biochem J; 2012 May; 443(3):735-46. PubMed ID: 22339555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.